Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)

Jihong Xu, W. Su, Chunmei Bai(Shanxi Medical University), Ying Yuan(Zhejiang Cancer Hospital), Elizabeth Li, X. Li, Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Shen(Peking University), Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxian Bai(Harbin Medical University), Jingyu Chen(Wuxi People's Hospital), Jiarui Li(Nanjing University of Chinese Medicine), Tianshu Liu(Sun Yat-sen University), Zhiheng Zhou(Southern Medical University Shenzhen Hospital), Ru Jia(Chinese PLA General Hospital), X. Wang(Qilu Hospital of Shandong University), Nong Xu(First Affiliated Hospital Zhejiang University), Z. Li(Wenzhou City People's Hospital)
Annals of Oncology
October 1, 2019
10.1093/annonc/mdz394.073
Cited by 17

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687